Summary The development of resistance to cisplatin (DDP) occurs rapidly both in vitro and in vivo, and constitutes a major obstacle to effective therapy. We have previously demonstrated that there is a highly synergistic interaction between tamoxifen (TAM) and DDP against cell lines representative of three different human cancers: melanoma, ovarian carcinoma and small-cell lung cancer. The purpose of these studies was to determine if TAM interferes with the development of resistance to DDP. T-289 Our previous clinical studies have demonstrated that tamoxifen (TAM) is an important component of a four-drug combination of dacarbazine, carmustine, DDP and TAM in the treatment of patients with metastatic melanoma (McClay et al., 1987). Omission of TAM from the regimen resulted in a decrease in the overall response rate from 51% to 10% (McClay et al., 1989) . Reincorporation of TAM into the regimen resulted in a return of the response rate to more than 50% (McClay et al., 1992a) . In a recent clinical study we demonstrated that, in patients with malignant melanoma documented to be resistant to single-agent DDP, the addition of TAM to the DDP programme on the next cycle resulted in a response rate of 30% (McClay et al., 1993a al., 1992b, 1993b). However, the DDP/TAM synergy was dependent on the sensitivity of the cell to TAM. DDP and TAM were still synergistic with respect to cytotoxicity in a DDP-resistant variant of the T-289 melanoma cell line, however they were not synergistic in killing a variant of the same cell line selected for resistance to TAM (McClay et al., 1993b) . Synergy was also absent in another melanoma cell line that was 4-fold resistant to TAM (McClay et al., 1992b) . (McClay et al., 1993c) .
Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines Summary The development of resistance to cisplatin (DDP) occurs rapidly both in vitro and in vivo, and constitutes a major obstacle to effective therapy. We have previously demonstrated that there is a highly synergistic interaction between tamoxifen (TAM) and DDP against cell lines representative of three different human cancers: melanoma, ovarian carcinoma and small-cell lung cancer. The purpose of these studies was to determine if TAM interferes with the development of resistance to DDP. T-289 melanoma cells and 2008 ovarian cancer cells were cultured with increasing concentrations of DDP ± TAM in an attempt to induce resistance to DDP. At various time points the cells were removed from culture and the degree of resistance to DDP was quantitated. Concurrent exposure to TAM and DDP decreased both the rate and the absolute magnitude of resistance to DDP in both melanoma and ovarian cancer cell lines. In the T-289 cell line the rate was decreased by a factor of 3.4 + 1.4 (P <0.05), while in the 2008 cell line the rate was decreased by a factor of 2.4 (P<0.01). TAM decreases the rate as well as the absolute magnitude of in vitro resistance to DDP in both melanoma and ovarian cancer cell lines. These data suggest that the concurrent administration of TAM and DDP may result in a delay in the development of resistance to DDP which may have important clinical implications in the design of DDP-containing regimens.
Our previous clinical studies have demonstrated that tamoxifen (TAM) is an important component of a four-drug combination of dacarbazine, carmustine, DDP and TAM in the treatment of patients with metastatic melanoma (McClay et al., 1987) . Omission of TAM from the regimen resulted in a decrease in the overall response rate from 51% to 10% (McClay et al., 1989) . Reincorporation of TAM into the regimen resulted in a return of the response rate to more than 50% (McClay et al., 1992a) . In a recent clinical study we demonstrated that, in patients with malignant melanoma documented to be resistant to single-agent DDP, the addition of TAM to the DDP programme on the next cycle resulted in a response rate of 30% (McClay et al., 1993a) .
Investigation of the interaction between DDP and TAM in vitro, using the mathematically rigorous technique of median effect analysis (Chou & Talalay, 1986) (McClay et al., 1992b (McClay et al., , 1993b . However, the DDP/TAM synergy was dependent on the sensitivity of the cell to TAM. DDP and TAM were still synergistic with respect to cytotoxicity in a DDP-resistant variant of the T-289 melanoma cell line, however they were not synergistic in killing a variant of the same cell line selected for resistance to TAM (McClay et al., 1993b) . Synergy was also absent in another melanoma cell line that was 4-fold resistant to TAM (McClay et al., 1992b (McClay et al., 1993c) .
Although the mechanism of synergy between TAM and DDP is not known at present, we hypothesised that if TAM can synergise with DDP to overcome DDP resistance then TAM may also be able to delay the development of DDP resistance by a similar mechanism. We report here that TAM can delay the development of DDP resistance in both T-289 and 2008 cells when given concurrently with DDP in cell culture.
Materials and methods
Cell lines and culture The T-289 melanoma cell line was derived from a tumour explant of a patient and has been passaged for >7 years (Taetle et al., 1987) . The 2008 cell line is an ovarian carcinoma line derived from a patient with an ovarian serous cystadenocarcinoma (Andrews et al., 1988) . Cells were cultured in 75 cm2 flasks (Corning, Corning, NY, USA) in RPMI-1640 (Irving Scientific, Santa Ana, CA, USA) supplemented with 10% fetal bovine serum, 50figml-' gentamicin (Gemini Bio-Products, Calabasa, CA, USA), 2 mM L-glutamine, 10 nM hydrocortisone, 5 fg ml-' insulin, 5 jg ml' human transferrin, 10 nM oestradiol and 5 ng ml-' selenium (Sigma, St Louis, MO, USA). S lar to the results obtained in the experiment with the melanoma cell line, concurrent exposure to both TAM and DDP resulted in a decrease in the absolute magnitude of resitance. At the start of the DDP escalation programme the IC,, for the control 2008 cells was 0.08 gm. After three escalations, the IC,O for the DDP (0.7 pm) alone-treated cells was 0.39 pM, while the IC,, for the DDP (0.7 pLM)/TAM (7.0 hiM)-treated cells was 0.22 M (see Table II (Furr & Jordan, 1984) , as well as to modulate established resistance to DDP (McClay et al., 1993a, b) and to drugs that are substrates for P-glycoproteinmediated efflux (Chatterjee & Harris, 1990 (Andrews & Howell, 1990) suggests that TAM can influence a genetic process funamental to the development of resisance. The failure to identify an effect on the biochemical pharmacology of either DDP or TAM, coupled with the observation that TAM can produce synergy (Chou & Talalay, 1986) with DDP even when added up to 48 h after the end of a I h exposure to DDP (McClay et al., 1992b) , is also consistent with an effect of TAM on a genetic process. To further support a TAM effect on genetic processes, TAM has recently been reported to form DNA adducts in vivo (Han & Liehr, 1992) . The fact that TAM can decrease the development of resistance in cell lines reprsentative of two types of human malignancy indicates that the biochemical or moklular genetic mechnis responsible for this interaction are common to multiple cell types. The question of whether or not the delay in the development of DDP riance might be of clical importance remains to be resolved. While there is strong evidence that treatment outcome is related to the initial sensitivity of the tumour to the drugs used (Gazdar et al., 1990) , the importance of the rate of the development of resistance to the effectiveness of treatment is unkcnown. Should the TAMinduced delay in the development of resistance be of importance in patients, one would expect at east an improvement in disease-free survival and possibly even in overall survival. As we have demonstrated, TAM has effects on both intrinsic sensitivity to DDP as well as on the rate of resistance development. Unfortunately, clinical end points such as diease-free and overall survival will not allow us to distinguish between the importance of these two TAM effects.
Further methods will need to be developed to help clarify these issues. 
